Contact

Representative before the EPO

Employment test 51 - 200 employees
Company dna j a kemp
no operation time available
1115.57
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Jane Helen Sexton has worked on the following 102 EPO patent applications which have been published in the last five years:

EP11721618

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

IPC classification:
A61K 31/4439, A61K 31/497, A61P 25/00, C07D 401/14, C07D 403/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 471/04, C07D 471/08, C07D 491/08
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11799027

C5AR ANTAGONISTS

IPC classification:
A61K 31/445, C07D 211/06
Agent:
Jane Helen Sexton, J A Kemp
Status:
PATENT GRANTED
EP11745858

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

IPC classification:
A61K 31/506, A61P 27/00, A61P 37/06, C07D 413/12, C07D 413/14
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11746709

AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME

IPC classification:
A61K 31/4427, A61K 31/501, A61K 31/5377, A61P 3/10, A61P 9/10, C07D 213/82, C07D 295/04, C07D 401/12, C07D 401/14, C07D 405/12, C07D 409/12, C07D 413/12, C07D 471/10
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12195108

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

IPC classification:
A61K 31/355, A61P 3/00, A61P 25/28
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP11709279

SYNTHESIS OF ALPHA-TOCOPHEROLQUINONE DERIVATIVES, AND METHODS OF USING THE SAME

IPC classification:
A61K 9/00, A61K 31/125, A61P 3/10, A61P 9/00, A61P 13/12, A61P 25/00, A61P 27/02, C07C 46/06, C07D 311/72
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11794108

PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF

IPC classification:
A61K 31/517, A61P 7/02, C07D 409/12
Applicant:
Novartis AG
Applicant:
Portola Pharmaceuticals, Inc.
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11854601

ANTI-CANCER REGIMEN

IPC classification:
A01N 31/04, A61K 31/05, A61K 31/065
Agent:
Jane Helen Sexton, J A Kemp
Status:
PATENT GRANTED
EP11775506

FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES

IPC classification:
A61K 31/122, A61P 27/02
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12711500

2,4 SUBSTITUTED PYRIMIDINEDIAMINES FOR USE IN DISCOID LUPUS

IPC classification:
A61K 31/506, A61P 17/00
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12716922

METHODS FOR INHIBITING ALLOGRAFT REJECTION

IPC classification:
A61K 31/397, A61P 37/06
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12722174

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

IPC classification:
A61K 31/4164, A61P 35/00, C07D 401/04, C07D 403/04, C07D 403/12, C07D 413/12, C07D 413/14, C07D 471/04, C07D 487/04, C07D 513/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11748095

PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS

IPC classification:
A01N 43/50, A61K 31/415, C07D 233/86
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP13163805

Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

IPC classification:
A61K 31/355, A61P 3/00, A61P 25/28
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12802981

MONITORING PROTEIN TRAFFICKING USING BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATION

IPC classification:
C12Q 1/02, G01N 33/53
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13151486

Combination therapy with a compound acting as a platelet ADP receptor inhibitor

IPC classification:
A61K 31/216, A61K 31/235, A61K 31/422, A61K 31/435, A61K 31/517, A61K 38/48, A61K 45/06, A61P 7/02
Applicant:
Portola Pharmaceuticals, Inc.
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12814970

METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS

IPC classification:
C07D 311/72
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12759802

NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS

IPC classification:
A61K 9/00
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP14161154

Anti-fungal formulation containing luliconazole

IPC classification:
A01N 43/50, A61K 31/4178, A61K 47/08, A61K 47/10, A61K 47/14, A61P 17/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11761204

2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

IPC classification:
A61K 31/706, A61P 31/16, C07H 7/06, C07H 21/04
Applicant:
Gilead Sciences Inc
Agent:
Jane Helen Sexton, J A Kemp
Agent:
Reitstötter Kinzebach & Partner GbR
Status:
GRANT OF PATENT INTENDED
EP14162839

NATURAL PRESERVATIVE ALTERNATIVES COMPRISING LONICERA EXTRACT AND COMPOSITIONS CONTAINING SAME

IPC classification:
A01N 65/00, A61K 8/97, A61K 31/74, A61K 36/355, A61Q 19/08
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14162075

Androgen receptor modulating compounds

IPC classification:
A61K 31/416, A61K 31/42, A61K 31/438, A61K 31/44, A61K 31/4523, A61K 31/497, A61K 31/5377, A61P 35/00, C07D 231/14, C07D 401/12, C07D 403/12, C07D 405/12, C07D 413/12, C07D 417/12
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12833512

ACETAMINOPHEN CONJUGATES, COMPOSITIONS AND METHODS OF USE THEREOF

IPC classification:
A61P 1/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12782062

COMPOUNDS AND METHODS OF TREATING DIABETES

IPC classification:
A61K 31/55, A61P 3/04, A61P 3/10
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12746946

COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

IPC classification:
A61K 31/55, A61P 9/12
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12783247

PROTEIN KINASE INHIBITORS

IPC classification:
A61K 31/4184, A61K 31/4188, A61P 35/00, C07D 401/14, C07D 403/04, C07D 413/04, C07D 471/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12787960

METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE) -6-YL]-5-FLUORO-N2- [3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE

IPC classification:
A61K 9/00, A61K 31/538, A61M 15/00
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12809907

TOPICAL FORMULATION FOR ADMINISTERING A COMPOUND

IPC classification:
A61K 9/00, A61K 31/506, A61K 47/10
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12798574

SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS

IPC classification:
A61K 31/44, C07D 403/04, C07D 403/14, C07D 405/14
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12814092

PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS

IPC classification:
A61K 31/519, A61P 31/12, C07D 487/04
Applicant:
Gilead Sciences Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP14165457

Tablets with improved friability

IPC classification:
A61K 9/20
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12801330

CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES

IPC classification:
A61K 31/05, A61K 31/122, C07C 39/19, C07C 43/23
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13161401

Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts

IPC classification:
A61K 31/58, A61P 7/10
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11815337

TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K

IPC classification:
A61K 31/122, A61P 25/14, A61P 25/16, A61P 25/28
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13746491

DETECTION OF INTRACELLULAR BINDING EVENTS BY MEASURING PROTEIN ABUNDANCE

IPC classification:
G01N 33/53
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12807735

TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES

IPC classification:
A01N 35/00, A61K 31/12, A61P 3/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13711222

SYNTHESIS OF POLYCYCLIC ALKALOIDS AND THEIR USE AS TGR5 AGONISTS

IPC classification:
A61K 31/437, A61K 31/55, A61K 31/553, A61K 31/554, A61P 3/00, C07D 471/04, C07D 471/14, C07D 471/22, C07D 487/04, C07D 487/14, C07D 491/147, C07D 491/22, C07D 495/14, C07D 495/22, C07D 498/04, C07D 513/04, C07D 513/14
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13719297

NEW ALPHA2 ADRENOCEPTOR AGONISTS

IPC classification:
A61K 31/4178, A61P 9/00, A61P 25/00, C07D 405/04, C07D 409/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP12798578

SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS

IPC classification:
A61K 31/4545, A61P 29/00, C07D 211/56, C07D 211/62, C07D 295/135, C07D 401/04, C07D 401/06, C07D 403/06, C07D 405/06, C07D 413/06, C07D 417/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12195147

Compositions and methods for inhibition of the JAK pathway

IPC classification:
A61K 31/506, A61P 27/02, A61P 37/06, C07D 413/12
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12789021

ACTIVATION OF HUMAN T-HELPER/INDUCER CELL, T-CYTOTOXIC/SUPPRESSOR CELL, B-CELL, AND NATURAL KILLER (NK)-CELLS AND INDUCTION OF NATURAL KILLER CELL ACTIVITY AGAINST K562 CHRONIC MYELOID LEUKEMIA CELLS WITH MODIFIED CITRUS PECTIN

IPC classification:
A61K 31/732, A61K 31/734, A61P 37/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13730284

CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS

IPC classification:
A61K 31/277, A61P 25/00, C07C 255/53, C07C 255/54, C07C 255/57, C07C 311/29, C07C 317/22, C07C 321/28, C07C 321/30, C07D 207/08, C07D 207/337, C07D 265/30, C07D 277/30, C07D 333/24, C07D 333/60
Agent:
Jane Helen Sexton, J A Kemp
Status:
PATENT GRANTED
EP13731237

AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS

IPC classification:
A61K 31/497, A61P 25/00, C07D 401/14, C07D 403/14
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13816414

METHODS OF INDUCING ANESTHESIA

IPC classification:
A61K 31/015, A61K 31/34, A61K 31/357, A61K 31/36, A61P 23/00
Applicant:
The Regents of the University of California
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP11731557

HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS

IPC classification:
A61K 31/4523, A61K 31/497, A61K 31/506, A61P 3/00, A61P 25/18, C07D 401/14, C07D 403/14, C07D 407/14, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04, C07D 487/04
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13163798

Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

IPC classification:
A61K 31/355, A61P 3/00, A61P 25/28
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13831088

COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

IPC classification:
A01N 43/38, A61K 31/405
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP13762705

BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS

IPC classification:
A61K 31/045, A61K 31/16, A61K 31/19, A61K 31/277, A61P 39/06, C07C 33/02, C07C 33/04, C07C 53/126, C07C 233/11, C07C 255/01
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP13765880

QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS

IPC classification:
A61K 31/045, A61P 39/06
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP13765904

TREATMENT FOR VITILIGO

IPC classification:
A61K 31/505, A61P 17/00
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11724480

HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS

IPC classification:
A61K 31/4535, A61K 31/454, A61K 31/4709, A61P 25/18, C07D 401/14, C07D 403/14, C07D 405/14, C07D 417/14, C07D 471/04, C07D 471/08, C07D 487/10
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13779617

N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

IPC classification:
A61K 31/166, C07C 237/30, C07C 237/44, C07C 255/58, C07C 323/63, C07D 209/08, C07D 213/81, C07D 213/82, C07D 215/48, C07D 239/42, C07D 317/58, C07D 319/18, C07D 333/38, C07D 405/12, C07D 417/12
Agent:
Jane Helen Sexton, J A Kemp
Status:
PATENT GRANTED
EP13789022

A VETERINARY METHOD OF ALLEVIATING NOISE AVERSION

IPC classification:
A61K 31/4174, A61P 43/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13859147

CXCR7 ANTAGONISTS

IPC classification:
C07D 403/06, C07D 403/12, C07D 403/14
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP13859762

DIAZOLE LACTAMS

IPC classification:
A61K 31/497
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP11841603

3-DEUTERO-POMALIDOMIDE

IPC classification:
A61K 31/40, C07B 59/00, C07D 401/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13830122

GALECTIN-3 PLASMAPHERESIS THERAPY

IPC classification:
A61M 1/34, A61P 35/00, G01N 33/50
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP14704450

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES

IPC classification:
A61K 31/505, A61P 1/00, A61P 1/04
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11766566

TREATMENT OF ATAXIA TELANGIECTASIA

IPC classification:
A61K 31/085, A61K 31/122, A61P 43/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11791943

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

IPC classification:
A61K 31/70, A61P 3/00, C07D 309/10
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP13876228

METHOD OF HYDROGASIFICATION OF BIOMASS TO METHANE WITH LOW DEPOSITABLE TARS

IPC classification:
C07C 1/20, C10G 1/06, C10G 47/24
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP14769964

NANO-CELLULOSE EDIBLE COATINGS AND USES THEREOF

IPC classification:
A23B 7/16, A23L 3/005, C09D 101/02
Applicant:
Oregon State University
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION WITHDRAWN
EP14722468

PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

IPC classification:
C07D 241/46, C07D 279/18
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP14720843

RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

IPC classification:
A61K 31/538, A61P 3/10, A61P 9/00, A61P 25/00, A61P 27/00, A61P 35/00, C07D 265/38, C07D 413/10
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP14722686

PROTEIN KINASE INHIBITORS

IPC classification:
A61K 31/4439, A61P 35/00, C07D 401/14, C07D 471/04
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11729018

PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS

IPC classification:
A61K 31/519, A61K 31/55, A61K 31/551, A61P 11/00, C07D 487/04, C07D 495/04, C07D 513/04
Applicant:
Gilead Sciences Inc
Agent:
Jane Helen Sexton, J A Kemp
Agent:
Reitstötter Kinzebach & Partner GbR
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15189792

COMPOSITION FOR HISTOCHEMICAL PROCESSING

IPC classification:
B82Y 30/00, G01N 1/30
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP11743709

METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS

IPC classification:
C07D 309/10, C07H 19/00
Applicant:
Gilead Sciences Inc
Agent:
Jane Helen Sexton, J A Kemp
Agent:
Schwarz & Partner
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14732802

CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

IPC classification:
A61K 31/16, A61K 31/215, A61K 31/341, C07C 69/732, C07C 69/95, C07C 235/30, C07C 235/78, C07D 307/33
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP14738676

BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS

IPC classification:
A61K 31/4704, A61P 29/00, C07D 215/36, C07D 241/44, C07D 403/12, C07D 413/12, C07D 413/14, C07D 417/12
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP15190273

4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

IPC classification:
A61K 31/16, A61K 31/445, A61P 21/00, A61P 25/00, A61P 25/16, A61P 27/00, C07C 235/78, C07C 317/28, C07D 207/27, C07D 213/40, C07D 223/04, C07D 233/61, C07D 295/02, C07D 295/185, C07D 295/192, C07D 295/24, C07D 307/14
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION IN PROGRESS
EP11719750

NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

IPC classification:
A61K 31/4375, A61K 31/444, A61K 31/4709, A61K 31/506, A61P 3/00, A61P 25/00, C07D 401/14, C07D 403/14, C07D 405/14, C07D 471/14
Applicant:
Amgen Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11770292

COMBINATIONS OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE

IPC classification:
A61K 31/4192, A61K 31/7076, A61P 35/00
Applicant:
Portola Pharmaceuticals, Inc.
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12195101

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

IPC classification:
A61K 31/355, A61P 3/00, A61P 25/28
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14792846

A VETERINARY METHOD FOR INDUCING EMESIS

IPC classification:
A61K 9/00, A61K 31/38, A61K 31/404, A61K 31/428, A61K 31/435, A61K 31/48, A61K 31/506, A61K 31/519, A61P 43/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP11757467

CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR

IPC classification:
A61K 31/44, A61P 7/02, C07D 213/75
Applicant:
Portola Pharmaceuticals, Inc.
Agent:
Jane Helen Sexton, J A Kemp
Status:
PATENT GRANTED
EP16157716

ANDROGEN RECEPTOR MODULATING COMPOUNDS

IPC classification:
C07D 231/12
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP11738258

METHOD FOR DIAGNOSIS

IPC classification:
G01N 33/68
Applicant:
United Arab Emirates University
Applicant:
University of Perugia (Università  degli studi di Perugia)
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11719748

BIFUNCTIONAL QUINOLINE DERIVATIVES

IPC classification:
A61K 31/4706, A61K 31/4709, A61P 11/00, C07D 215/54, C07D 401/12, C07D 409/14, C07D 413/12
Applicant:
Gilead Sciences Inc
Agent:
Jane Helen Sexton, J A Kemp
Agent:
Reitstötter Kinzebach & Partner GbR
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11730116

2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES

IPC classification:
A61K 31/5383, A61P 29/00, A61P 37/00, C07D 498/04
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14863272

BIOCHAR WATER TREATMENT

IPC classification:
C02F 1/28, C02F 1/56, C02F 1/78, C02F 9/08, C02F 101/10, C02F 103/06
Applicant:
University Of Idaho - Office of Technology Transfer
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP14819038

METHOD FOR PREPARING DRY POWDER INHALATION COMPOSITIONS

IPC classification:
A61K 9/72, A61K 31/167, A61K 31/58
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP14867718

CCR6 COMPOUNDS

IPC classification:
A61K 31/44
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP14828102

PHARMACEUTICAL PROCESS AND INTERMEDIATES

IPC classification:
C07F 9/6561
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15703314

BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/498, A61K 31/536, A61P 29/00, A61P 35/00, A61P 37/00, C07D 401/14, C07D 413/04, C07D 413/14
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15710299

PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) PROTEINS AND ANTIGENS

IPC classification:
A61K 39/215
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15754999

COMPOUNDS COMPRISING A HIBONITE STRUCTURE

IPC classification:
B01J 19/24, C01B 3/40
Applicant:
Oregon State University Advantage
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15707833

COMPOSITION AND METHOD FOR PROMOTING REDUCTION OF HEAT STRESS IN ANIMALS

IPC classification:
A61K 31/716, A61K 31/736, A61K 35/02, A61K 38/47, A61K 45/06, A23K 20/20, A23K 20/163, A23K 20/28
Applicant:
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15760948

ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING

IPC classification:
A61K 31/16, A61K 31/21, A61K 31/33, A61P 1/04, A61P 1/16, A61P 29/00, A61P 31/00, C07C 229/44, C07D 231/56, C07D 235/06, C07D 263/56, C07D 265/36, C07D 275/04, C07D 277/64, C07D 279/16, C07D 309/30, C07D 319/18, C07D 339/08
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15712480

FEED COMPONENTS AND METHOD FOR MAKING AND USING

IPC classification:
A23K 50/00, A23K 10/38
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15726218

PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES

IPC classification:
A61K 31/517, A61P 25/00, C07D 239/96, C07D 405/04, C07D 405/06
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP16196059

IMMUNOMODULATING COMPOSITION

IPC classification:
A01N 31/04, A61K 31/05, A61K 31/065
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION PUBLISHED
EP15727805

COMBINATION, COMPOSITION, AND METHOD OF ADMINISTERING THE COMBINATION OR COMPOSITION TO ANIMALS

IPC classification:
A61K 36/73, A61K 36/896, A61P 33/00
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP16184096

REDUCTION OF GALECTIN LEVELS BY PLASMAPHERESIS

IPC classification:
A61M 1/34, C07K 16/18, G01N 33/68
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION PUBLISHED
EP15811614

USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY

IPC classification:
A61K 31/428, A61K 31/4439, A61P 31/04
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP16200325

METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE

IPC classification:
A61K 9/00, A61K 31/56, A61K 31/57, A61K 47/34
Applicant:
ALLERGAN INC
Agent:
Jane Helen Sexton, J A Kemp
Status:
APPLICATION PUBLISHED
EP15753856

QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS

IPC classification:
A61K 31/4706, A61K 31/496, A61K 31/5377, A61P 35/00, C07D 215/40, C07D 401/04, C07D 401/12, C07D 401/14, C07D 405/04, C07D 409/04
Applicant:
Rigel Pharmaceuticals Inc
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED
EP15834042

HOMOGENOUS THERMAL SHIFT LIGAND BINDING ASSAY

IPC classification:
G01N 33/58, G01N 33/68
Agent:
Jane Helen Sexton, J A Kemp
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature